Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers-Reference-Cited by-同舟云学术

Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers

Published:2018-09-25 Issue:5 Volume:104 Page:1417-1428
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Dunn Lara A¹²,Sherman Eric J¹²,Baxi Shrujal S¹²,Tchekmedyian Vatche¹,Grewal Ravinder K³,Larson Steven M³,Pentlow Keith S⁴,Haque Sofia³,Tuttle R Michael¹,Sabra Mona M¹,Fish Stephanie¹,Boucai Laura¹,Walters Jamie¹,Ghossein Ronald A⁵,Seshan Venkatraman E⁶,Ni Ai⁶,Li Duan³,Knauf Jeffrey A⁷,Pfister David G¹²,Fagin James A¹²⁷,Ho Alan L¹²^ORCID

Affiliation:

1. Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

2. Department of Medicine, Weill Cornell Medical College, New York, New York

3. Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York

4. Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York

5. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York

6. Department of Epidemiology–Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York

7. Human Oncology and Pathogenesis, Memorial Sloan-Kettering Cancer Center, New York, New York

Funder

Genentech

National Cancer Institute

Geoffrey Beene Cancer Research Center

Cycle for Survival

Publisher

The Endocrine Society

Subject

Biochemistry, medical,Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/104/5/1417/28224398/jc.2018-01478.pdf

Reference34 articles.

1. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial;Brose;Lancet,2014

2. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment;Cabanillas;Cancer,2015

3. Phase II trial of sorafenib in metastatic thyroid cancer;Kloos;J Clin Oncol,2009

4. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer;Schlumberger;N Engl J Med,2015

5. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer;Blevins,2014

Cited by 181 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detection of the BRAFV600E Mutation in Circulating Free Nucleic Acids as a Biomarker of Thyroid Cancer: A Review;Journal of Clinical Medicine;2024-09-12

2. An update on redifferentiation strategies for radioactive iodine-refractory differentiated thyroid carcinoma;Endocrine;2024-09-04

3. The value of preoperative molecular testing in the management of Bethesda V and Bethesda VI thyroid tumors;Hormones;2024-09-03

4. Predictive biomarkers in thyroid cancer in the current molecular-morphology paradigm;Surgical and Experimental Pathology;2024-08-14

5. Paraplegic Patient with Metastatic Papillary Thyroid Cancer: A Multidisciplinary Approach to Radioactive Iodine Therapy Safety and Efficacy Strategy;Journal of Nuclear Medicine;2024-07-11